Franchini M, Favaloro EJ, Lippi G. Mild hemophilia A. J Thromb Haemost 2010; 8(3): 421-32.
Mansouritorghabeh H. Clinical and Laboratory Approaches to
Hemophilia a. Iran J Med Sci 2015; 40(3): 194-205.
Franchini M, Mannucci PM. Hemophilia A in the third millennium. Blood Rev 2013; 27(4): 179-84.
Schulman S. Treatment of Hemophilia: Mild Hemophilia 2012; 41. p. 1-10. Available from: http://www1.wfh.org/publication/files/pdf-1192.pdf.
Oldenburg J, Pavlova A. Discrepancy between one-stage and chromogenic factor VIII activity assay results can lead to misdiagnosis of haemophilia A phenotype. Hämostaseologie 2010; 30(4): 207-11.
Rodgers SE, Duncan EM, Barbulescu DM, Quinn DM, Lloyd JV. In vitro kinetics of factor VIII activity in patients with mild haemophilia A and a discrepancy between one-stage and twostage factor VIII assay results. Br J Haematol 2007; 136(1): 138-45.
Potgieter JJ, Damgaard M, Hillarp A. One-stage vs.
chromogenic assays in haemophilia A. Eur J Haematol 2015; 94 Suppl 77: 38-44.
Duncan EM, Rodgers SE, McRae SJ. Diagnostic testing for mild hemophilia a in patients with discrepant one-stage, two-stage, and chromogenic factor VIII: C assays. Semin Thromb Hemost 2013; 39(3): 272-82.
Trossaërt M, Boisseau P, Quemener A, Sigaud M, Fouassier M, Ternisien C, et al . Prevalence, biological phenotype and genotype in moderate/mild hemophilia A with discrepancy between one-stage and chromogenic factor VIII activity. J Thromb Haemost 2011; 9(3): 524-30.
Cid AR, Calabuig M, Cortina V, Casaña P, Haya S, Moret A, et al. One-stage and chromogenic FVIII:C assay discrepancy in mild haemophilia A and the relationship with the mutation and bleeding phenotype. Haemophilia 2008; 14(5): 1049-54.
Trossaert M, Lienhart A, Nougier C, Fretigny M, Sigaud M, Meunier S, et al. Diagnosis and management challenges in patients with mild hemophilia A and discrepant FVIII measurements. Haemophilia 2014; 20(4): 550-8.
Sci J Iran Blood Transfus Organ 2017; 13(4): 277-283
Original Article
The results of two methods of factor VIII:C in patients with hemophilia A
1Blood Transfusion Research Center, High Institute for Research and Education in Transfusion Medicine, Tehran, Iran 2School of Medicine, Tehran University of Medical Sciences, Tehran, Iran 3Thrombosis Hemostasis Research Center, Tehran University of Medical Sciences, Tehran, Iran
Abstract Background and Objectives
FVIII activity (FVIII:C) is measured by clotting or chromogenic methods. The results of these methods may be different in some cases of hemophilia A that can cause misdiagnosis. The Aim of this study is to assess the results of two methods of F VIII:C assay in patients with hemophilia A.
Materials and Methods
In A descriptive survey research, FVIII:C level was measured using one-stage and chromogenic assays in 73 hemophilia A known patients. The data were analyzed by t-test and SPSS 22 statistical method.
Results
From 73 patients in this study, the range of FVIII:C assay by one-stage method was 4% to 81% ( mean = 22.7 , SD = 14.8 ) and the range of FVIII:C assay by chromogenic method was 1% to 123 % ( mean=16.5 , SD = 21 ).
Conclusions
For prevention of misdiagnosis, it is recommended to use two methods of FVIII:C assays for diagnosis of patients with hemophilia A.
Key words: Hemophilia A, Factor VIII, Prevalence
Received: 8 Mar 2016 Accepted: 8 Aug 2016
Correspondence: Ahmadinejad M., MD. Pathologist. Assistant Professor of Blood Transfusion Research Center, High Institute for Research and Education in Transfusion Medicine.
P.O.Box: 14665-1157, Tehran, Iran. Tel: (+9821) 88212459; Fax: (+9821) 88601555
E-mail: minooam26@yahoo.com
Vossough Shirayeh F, Ahmadinejad M, Toogeh G, karimi K, Tabatabaei M. The results of two methods of factor VIII:C in patients with hemophilia A. Sci J Iran Blood Transfus Organ 2016; 13 (4) :277-283 URL: http://bloodjournal.ir/article-1-1028-en.html